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Supplemental Figure 1. Spleen [68Ga]Pentixafor uptake is not associated with PFS/OS in different entities.
Kaplan-Meier survival curves of progression-free survival (PFS) and overall survival of different solid tumor entities, 
comparing patients with low to patients with high spleen-to-liver ratio (SUVmaxSpleen/SUVmeanLiver), adrenal 
cancer, PFS: low, n = 13, high, n = 13, OS: low, n = 13, high, n = 13; DSRCT, PFS: low, n = 5, high, n = 4,  OS: low, 
n = 5, high, n = 4; neuroendocrine tumors, PFS: low, n = 13, high, n = 11, OS: low, n = 13, high, n =11; NSCLC, 
PFS: low, n = 3, high, n = 3, OS: low, n = 3, high, n = 3; pancreatic adenocarcinoma, PFS: low, n = 4, high, n = 4, 
OS: low, n = 4, high, n = 4; SCLC, PFS: low, n = 5, high, n = 4, OS: low, n = 5, n = 4.
All statistical analyses were performed using log-rank (Mantel-Cox) test. P values as indicated on the graphs. 
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Supplemental Figure 2. Spleen [68Ga]Pentixafor uptake is not associated with PFS/OS in all entities, or 
adrenal cancers and neuroendocrine tumors, when comparing the highest to the lowest quartile of spleen 
CXCR4 expression. 
A Kaplan-Meier survival curves of progression-free survival, comparing the quartile with highest to the quartile of 
lowest spleen-to-liver ratio (SUVmaxSpleen/SUVmeanLiver). All cancers: low, n = 30, high, n = 30; adrenal cancers: 
low, n = 6, high, n = 6; neuroendocrine tumors: low, n = 6, high, n = 6. 
B Kaplan-Meier survival curves of overall survival, comparing the quartile with highest to the quartile of lowest 
spleen-to-liver ratio (SUVmaxSpleen/SUVmeanLiver). All cancers: low, n = 30, high, n = 30; adrenal cancers: low, n = 
6, high, n = 6; neuroendocrine tumors: low, n = 6, high, n = 6. 
All statistical analyses were performed using log-rank (Mantel-Cox) test. P values as indicated on the graphs.
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Supplemental Figure 3. Spleen [68Ga]Pentixafor is positively associated with platelet counts in solid 
cancers. 
Correlations of spleen-to-liver ratios (SUVmaxSpleen/SUVmeanLiver) of all patients in this study with serum CRP 
levels (mg/dl), n = 128; serum LDH levels (U/l), n = 121; blood hemoglobin levels (g/dl), n = 138; peripheral 
leucocyte count (/nl), n = 138 and peripheral platelet count (/nl), n = 138. 





R2 = 0.0175 
P = 0.4784 R2 = 0.0318 P = 0.6464 R2 = 0.0366 P = 0.3596 
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Supplemental Figure 4. Spleen [68Ga]Pentixafor uptake is not associated with serum CRP levels.
Correlations of spleen-to-liver ratios (SUVmaxSpleen/SUVmeanLiver) with serum CRP levels (mg/dl) in patients with 
adrenal cancer, n = 31; DSRCT, n = 9; neuroendocrine tumor, n = 25; NSCLC, n = 9; pancreatic adenocarcinoma, n 
= 7 and SCLC, n = 9.
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Supplemental Figure 5. Spleen [68Ga]Pentixafor uptake is not associated with serum LDH levels.  
Correlations of spleen-to-liver ratios (SUVmaxSpleen/SUVmeanLiver) with serum LDH levels (U/l) in patients with 
adrenal cancer, n = 31; DSRCT, n = 9; neuroendocrine tumor, n = 25; NSCLC, n = 9; pancreatic adenocarcinoma, n 
= 7 and SCLC, n = 9.
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Supplemental Figure 6. Spleen [68Ga]Pentixafor uptake is not associated with blood hemoglobin levels.  
Correlations of spleen-to-liver ratios (SUVmaxSpleen/SUVmeanLiver) with blood hemoglobin levels (g/dl) in patients with 
adrenal cancer, n = 31; DSRCT, n = 9; neuroendocrine tumors, n = 25; NSCLC, n = 9; pancreatic adenocarcinoma, n = 7 
and SCLC, n = 10.  
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Supplemental Figure 7. Spleen [68Ga]Pentixafor is not associated with leucocyte count and/or platelet 
counts in some entities.
A Correlations of spleen-to-liver ratios (SUVmaxSpleen/SUVmeanSpleen) with peripheral leucocyte count in patients 
with adrenal cancer, n = 31; DSRCT, n = 9; pancreatic adenocarcinoma, n = 9 and SCLC, n = 10. 
B Correlation of spleen-to-liver ratios (SUVmaxSpleen/SUVmeanSpleen) with peripheral platelet count in patients with 
DSRCT, n = 9 and pancreatic adenocarcinoma, n = 9. 
All statistical analyses were performed using simple linear regression. R2 and P values as indicated on the graphs.   
